A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity

BACKGROUND: Relatively poor penetration and retention in tumor tissue has been documented for large molecule drugs including therapeutic antibodies and recombinant immunoglobulin constant region (Fc)-fusion proteins due to their large size, positive charge, and strong target binding affinity. Theref...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lily, Yu, Haijia, Huang, Xin, Tan, Hongzhi, Li, Song, Luo, Yan, Zhang, Li, Jiang, Sumei, Jia, Huifeng, Xiong, Yao, Zhang, Ruliang, Huang, Yi, Chu, Charles C, Tian, Wenzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466810/
https://www.ncbi.nlm.nih.gov/pubmed/25881012
http://dx.doi.org/10.1186/s12885-015-1140-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466810/
https://www.ncbi.nlm.nih.gov/pubmed/25881012
http://dx.doi.org/10.1186/s12885-015-1140-1

Ejemplares similares